The contract manufacturing market for Pharmaceuticals in China is estimated to be worth USD 13 billion in 2030, predicts {Roots Analysis}
Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world   Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market,...
0 Commenti 0 condivisioni